TransMedics Group, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue:
Net product revenue	$113,419	$87,677	$332,549	$272,011
Service revenue	89,586	56,146	234,337	172,719
Total revenue	203,005	143,823	566,886	444,730
Cost of revenue:
Cost of net product revenue	23,570	18,687	73,444	54,420
Cost of service revenue	60,778	40,561	160,426	120,918
Total cost of revenue	84,348	59,248	233,870	175,338
Gross profit	118,657	84,575	333,016	269,392
Operating expenses:
Research, development and clinical trials	29,182	15,260	85,693	48,354
Selling, general and administrative	61,334	46,015	182,149	133,728
Total operating expenses	90,516	61,275	267,842	182,082
Income from operations	28,141	23,300	65,174	87,310
Other income (expense):
Interest expense	(7,271)	(3,491)	(21,666)	(10,428)
Interest income and other income (expense), net	3,231	3,222	8,483	9,007
Total other expense, net	(4,040)	(269)	(13,183)	(1,421)
Income before income taxes	24,101	23,031	51,991	85,889
(Provision) benefit for income taxes	(7,028)	1,288	(12,921)	(981)
Net income	$17,073	$24,319	$39,070	$84,908
Net income per share:
Basic	$0.49	$0.71	$1.13	$2.50
Diluted	$0.46	$0.66	$1.08	$2.28
Weighted average common shares outstanding:
Basic	34,691,046	34,112,452	34,552,868	33,917,006
Diluted	40,833,175	40,748,023	36,077,206	40,410,208

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.